Novartis is touting new data that demonstrates its experimental pill for multiple sclerosis performed better than Biogen Idec's established injectable Avonex. And Novartis says it is on track to file for an approval in late 2009. Researchers reported fewer relapses for FTY720 compared to Avonex. Report